Becton Dickinson Change in Accounts Receivable 2010-2025 | BDX
Becton Dickinson annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Becton Dickinson change in accounts receivable for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Becton Dickinson change in accounts receivable for the twelve months ending June 30, 2025 was $-0.453B, a 56.21% increase year-over-year.
- Becton Dickinson annual change in accounts receivable for 2024 was $-0.453B, a 56.21% increase from 2023.
- Becton Dickinson annual change in accounts receivable for 2023 was $-0.29B, a 1006.25% decline from 2022.
- Becton Dickinson annual change in accounts receivable for 2022 was $0.032B, a 152.46% decline from 2021.
Becton Dickinson Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$-453 |
| 2023 |
$-290 |
| 2022 |
$32 |
| 2021 |
$-61 |
| 2020 |
$-53 |
| 2019 |
$-51 |
| 2018 |
$-170 |
| 2017 |
$-93 |
| 2016 |
$-128 |
| 2015 |
$-2 |
| 2014 |
$-7 |
| 2013 |
$-1 |
| 2012 |
$-30 |
| 2011 |
$-27 |
| 2010 |
$-74 |
| 2009 |
$-82 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$57.228B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
